ALEX Y. NIE (聂焰) - Foley & Lardner LLP
ALEX Y. NIE (聂焰) - Foley & Lardner LLP
ALEX Y. NIE (聂焰) - Foley & Lardner LLP
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ASSOCIATE<br />
A<strong>NIE</strong>@FOLEY.COM<br />
975 PAGE MILL ROAD<br />
PALO ALTO, CA 94304-1013<br />
(650) 251-1124<br />
<strong>ALEX</strong> Y. <strong>NIE</strong> (聂焰)<br />
聂焰博士,美国富理达律师事务所律师,是该所化学、生物技<br />
术和制药执业组,电子学执业组,和生命科学工业团队的成<br />
员。<br />
聂博士的事务包括专利申请以及相关的法律咨询。他的主要技<br />
术领域包括生命科学技术以及信息产业。<br />
在生命科学方面,除了传统的生物技术和化学制药以外,聂博<br />
士的执业重点也特别包括个性化医疗,生物和化学信息学,体<br />
外诊断和干细胞技术。<br />
在信息产业方面,聂博士的职业包括普通的软件和硬件技术,<br />
比如那些涉及到人工智能,机器学习,数据加密,移动平台,<br />
和数字电路设计。<br />
聂博士同时也是富理达律师事务所的中国开拓组队成员。他撰<br />
写了一些关于中国新专利法的文章,并且被邀请在由中国国务<br />
院法制办和美国商务部 2009 年在洛杉矶组织的中美法制交流<br />
会上演讲探讨了中国的专利执法现状。他的演讲内容随即被美<br />
国之音引用和报道。聂博士还于 2009 年代表加州再生医学研<br />
究院和中国科技部商定签署了合作意向书。<br />
在从事法律行业以前,聂博士曾是美国强生公司的强生药物研<br />
发有限公司的资深研究员。聂博士在强生公司的七年的研究方<br />
向是寻找签订用来评估小分子药物安全性的新型技术手段。他<br />
同时也是强生公司在关键途径研究所的代表。关键途径研究所<br />
是一个由美国食品和药物管理局(FDA)组织协调的,世界制<br />
药行业的跨公司的合作机构。其成立目标是验证新的科技手段<br />
来达到改进药物的审批过程。聂博士也参与了强生公司的中国<br />
行动计划,在其中帮助强生公司考评一些中国公司的技术能<br />
力。<br />
聂博士在 1993 年获得武汉大学生物化学学士的学位,然后在<br />
1996 年获得中国科技大学分子生物学的硕士学位。此后他留<br />
学美国并在 2001 年获得罗格斯大学生物化学博士和计算机科<br />
学硕士两个学位。2008 年,聂博士再次获得美国罗格斯大学<br />
纽瓦克法学院的法律博士学位。<br />
聂博士发表了 25 篇同行审查的科学论文,也在两本科学书籍<br />
©2011 <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 North Clark Street, Chicago, IL 60654 • 312.832.4500
中著写章节。他曾被授予过美国健康研究院(NIH)的研究基金<br />
并在多个科学组织担任委员会成员。这些组织包括国际生命科<br />
学组织属下的健康和环境科学研究所,关键途径研究所,和<br />
FDA 的药物基因组数据标准委员会。聂博士曾被邀请担任<br />
2006 年在法国巴黎召开的药物信息协会年会的分会的主席并<br />
发表演讲。<br />
聂博士是美国加州的注册律师,并持有美国专利和商标局的注<br />
册执照。<br />
聂博士的代表论文:<br />
Nie, “USPTO’s 2010 – 2015 Strategic Plan (中文<br />
版标题:美国专利商标局的 2010-2015 战略规划),”<br />
published in <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> Fall 2010 edition<br />
of Legal News: China Quarterly Newsletter, Eye on<br />
China (October 2010)<br />
Best, Carsten and Nie, "Ninth Circuit," Ch. 10 in<br />
Patent Obviousness in the Wake of KSR International<br />
Co. v. Teleflex Inc., (Paul. M. Rivard and Alan<br />
Gardner, eds., 2010)<br />
Wright Bonnilla, Brinckerhoff, Konski and Nie,<br />
"Patent Eligibility of Personalized Medicine<br />
Method Claims Confirmed by Federal Circuit in<br />
Prometheus Labs., Inc. v. Mayo," published in<br />
<strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> Legal News Alert: Biotechnology<br />
& Pharmaceutical (September 2009)<br />
Konski, Brinckenhoff and Nie, "Genes Under the<br />
Microscope – Novel or Not?" published in<br />
Intellectual Property Today (July 2009)<br />
Nie, "Introduction to the U.S. Patent Reform Act<br />
of 2009(中文版标题:2009 年美国专利改革法案介<br />
绍)," published in <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> Summer<br />
2009 Eye on China Newsletter (August 2009)<br />
Zhao, Nie and Tang, "PRC Supreme People’s<br />
Court Patent Infringement Enforcement Guidance:<br />
The "Draft" Published for Comments by the Patent<br />
Community," published in <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong><br />
Legal News Alert: China (July 2009)<br />
Fielden and Nie et al., "Interlaboratory evaluation<br />
of genomic signatures for predicting<br />
carcinogenicity in the rat," published in<br />
Toxicological Sciences (vol 103, pages 28-34,<br />
2008)<br />
©2011 <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 North Clark Street, Chicago, IL 60654 • 312.832.4500
Nie et al., "Predictive Toxicogenomics Approaches<br />
Reveal Underlying Molecular Mechanisms of<br />
Nongenotoxic Carcinogenicity," published in<br />
Molecular Carcinogenesis (vol 45, pages 914-933,<br />
2006)<br />
Nie, McMillian and Lord, "Toxicogenomics in Drug<br />
Safety Evaluation: Bridging Drug Discovery and<br />
Development," published in Carmen and<br />
Hardiman eds. Biochips as Pathways to Drug<br />
Discovery. Florida: Taylor & Francis Group (pages<br />
69-96, 2006)<br />
代表讲座和简报:<br />
"U.S. Perspective of Patent Enforcement in China,"<br />
2009 U.S.-China Legal Exchange, Los Angeles,<br />
California (October 12, 2009)<br />
"An Analysis of the Characteristics of Licensed<br />
Clean Tech Patents from Publicly Announced<br />
Commercialization Deals," the 5th International<br />
Congress of Nano-Bio Clean Tech 2008<br />
conference, San Francisco, California (October<br />
27-30, 2008)<br />
"Preparing the Critical Path to Acceptance of<br />
Toxicogenomic Data in Drug Safety Evaluation,"<br />
the 2007 Joint Statistics Meeting, Salt Lake City,<br />
Utah (July 26 – August 2, 2007)<br />
"Bioinformatics Lighting a New Path to Better<br />
Drug Development," the Drug Information<br />
Association 18th Annual EuroMeeting, Paris,<br />
France (March 6-8, 2006)<br />
©2011 <strong>Foley</strong> & <strong>Lardner</strong> <strong>LLP</strong> • Attorney Advertisement • Prior results do not guarantee a similar outcome • 321 North Clark Street, Chicago, IL 60654 • 312.832.4500